Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70-year nationwide cohort
- PMID: 33738986
- PMCID: PMC9543793
- DOI: 10.1111/aos.14847
Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70-year nationwide cohort
Abstract
Purpose: While early treatment of posterior uveal melanoma can save the eye, the effect of early treatment on survival remains unknown. Therefore, we aimed to determine whether the tumour size at diagnosis has changed over time, and if this has affected survival rates of patients with posterior uveal melanoma in Denmark.
Methods: Nationwide retrospective cohort study linking data from registry-based resources to data from clinical charts and pathology records. Including all Danish patients diagnosed with posterior uveal melanoma from 1943 to 2017. Incidence rates were estimated as annual percentage change (APC) overall and by American Joint Committee on Cancer (AJCC) tumour sizes. The age-period-cohort model was applied to estimate the relative risk of calendar period. The cox proportional hazards model, relative survival Kaplan-Meier curves and cumulative incidence curves were applied to estimate the effect of calendar period on survival.
Results: An overall increase in incidence rate of uveal melanoma was found (APC = 0.25%, 0.08-0.42; 95% CI). This was due to increasing incidence rate of AJCC T1 + T2 tumours (APC = 0.97%, 0.57-1.37; 95% CI), whereas no increase in incidence rates of AJCC T3 + T4 tumours was found (APC = -0.01%, -0.26 to 0.25; 95% CI). The disease-specific survival improved with calendar period for all tumour sizes (HR = 0.988; 0.984-0.993; 95% CI).
Conclusion: Increasing incidence rate and improved survival rate for uveal melanoma was found concordantly with a decrease in tumour size during a 70-year period.
© 2021 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Figures







Similar articles
-
The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma.Invest Ophthalmol Vis Sci. 2014 Dec 23;56(1):438-44. doi: 10.1167/iovs.14-15571. Invest Ophthalmol Vis Sci. 2014. PMID: 25537201
-
Increasing Incidence of Posterior Uveal Melanoma in Scandinavia 1960-2022: A Tri-National Study.Am J Ophthalmol. 2025 Jun;274:131-141. doi: 10.1016/j.ajo.2025.03.002. Epub 2025 Mar 5. Am J Ophthalmol. 2025. PMID: 40054546
-
Validation of Four Prognostic Models for Metastatic Posterior Uveal Melanoma in a Danish Cohort.Invest Ophthalmol Vis Sci. 2025 May 1;66(5):38. doi: 10.1167/iovs.66.5.38. Invest Ophthalmol Vis Sci. 2025. PMID: 40423622 Free PMC article.
-
Posterior uveal melanoma. The Swedish perspective.Acta Ophthalmol Scand. 1996 Aug;74(4):315-29. doi: 10.1111/j.1600-0420.1996.tb00701.x. Acta Ophthalmol Scand. 1996. PMID: 8883543 Review.
-
Uveal melanoma: estimating prognosis.Indian J Ophthalmol. 2015 Feb;63(2):93-102. doi: 10.4103/0301-4738.154367. Indian J Ophthalmol. 2015. PMID: 25827538 Free PMC article. Review.
Cited by
-
Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study.Cancers (Basel). 2024 Sep 30;16(19):3346. doi: 10.3390/cancers16193346. Cancers (Basel). 2024. PMID: 39409966 Free PMC article.
-
Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.Cancers (Basel). 2021 Dec 25;14(1):96. doi: 10.3390/cancers14010096. Cancers (Basel). 2021. PMID: 35008260 Free PMC article. Review.
-
Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study.Trials. 2023 Mar 26;24(1):230. doi: 10.1186/s13063-023-07245-9. Trials. 2023. PMID: 36966349 Free PMC article.
-
Uveal Melanoma Patients Have a Distinct Metabolic Phenotype in Peripheral Blood.Int J Mol Sci. 2023 Mar 7;24(6):5077. doi: 10.3390/ijms24065077. Int J Mol Sci. 2023. PMID: 36982149 Free PMC article.
-
Worldwide Incidence of Ocular Melanoma and Correlation With Pigmentation-Related Risk Factors.Invest Ophthalmol Vis Sci. 2023 Oct 3;64(13):45. doi: 10.1167/iovs.64.13.45. Invest Ophthalmol Vis Sci. 2023. PMID: 37902747 Free PMC article.
References
-
- Ah‐Fat F & Damato B (1998): Delays in the diagnosis of uveal melanoma and effect on treatment. Eye 12: 781–782. - PubMed
-
- Andersson TML, Rutherford MJ & Humphreys K (2017): Assessment of lead‐time bias in estimates of relative survival for breast cancer. Cancer Epidemiol 46: 50–56. - PubMed
-
- Bagger M, Andersen MT, Andersen KK, Heegaard S, Andersen MK & Kiilgaard JF (2014): The prognostic effect of American Joint Committee on Cancer staging and genetic status in patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 56: 438–444. - PubMed
-
- Bagger M, Smidt‐Nielsen I, Andersen MK, Jensen PK, Heegaard S, Andersen KK, Friis S & Kiilgaard JF (2018): Long‐term metastatic risk after biopsy of posterior uveal melanoma. Ophthalmology 1–8. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical